55 related articles for article (PubMed ID: 33691550)
1. Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis.
Fang YS; Wu Q; Zhao HC; Zhou Y; Ye L; Liu SS; Li XX; Du WD
Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1065-1076. PubMed ID: 33691550
[No Abstract] [Full Text] [Related]
2. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma.
Jang ES; Jeong SH; Kim JW; Choi YS; Leissner P; Brechot C
PLoS One; 2016; 11(3):e0151069. PubMed ID: 26986465
[TBL] [Abstract][Full Text] [Related]
3. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Norman JS; Li PJ; Kotwani P; Shui AM; Yao F; Mehta N
J Hepatol; 2023 Dec; 79(6):1469-1477. PubMed ID: 37683735
[TBL] [Abstract][Full Text] [Related]
4. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
Li H; Liu H; Yan LJ; Ding ZN; Zhang X; Pan GQ; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Yan YC; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(11):1159-1167. PubMed ID: 37929312
[TBL] [Abstract][Full Text] [Related]
5. Integrated Predictors by Propensity Scoring With Tumor Markers and Plasma Levels of microRNA-21-5p, IL-17, and IL-10 Complement Early Detection of Hepatocellular Carcinoma in Patients With Liver Cirrhosis.
Machida M; Ambo M; Mishina R; Hada N; Tachibana F; Yamashita M; Konda A; Tsuji K
Technol Cancer Res Treat; 2023; 22():15330338231212084. PubMed ID: 37960842
[No Abstract] [Full Text] [Related]
6. Chinese expert consensus statement on the clinical application of AFP/AFP-L3%/DCP using GALAD and GALAD-like algorithm in HCC.
Huang C; Xiao X; Zhou L; Chen F; Wang J; Hu X; Gao C;
J Clin Lab Anal; 2023 Dec; 37(23-24):e24990. PubMed ID: 38063322
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma.
Li B; Li B; Guo T; Sun Z; Li X; Li X; Wang H; Chen W; Chen P; Mao Y
Biomed Res Int; 2017; 2017():5358615. PubMed ID: 28540298
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of biomarkers of hepatocellular carcinoma.
Mohammed AF; Chen X; Li C
Bratisl Lek Listy; 2024; 125(2):102-106. PubMed ID: 38219063
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis.
Yang M; Zhang X; Liu J
PLoS One; 2019; 14(11):e0225170. PubMed ID: 31730646
[TBL] [Abstract][Full Text] [Related]
10. A wide scan of plasma proteins demonstrates thioredoxin reductase 1 as a potential new diagnostic biomarker for hepatocellular carcinoma.
Zenlander R; Fredolini C; Schwenk JM; Rydén I; Påhlsson P; Löwbeer C; Eggertsen G; Stål P
Scand J Gastroenterol; 2023; 58(9):998-1008. PubMed ID: 37017178
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of serum derived exosomes for hepatocellular carcinoma: a systematic review and meta-analysis.
Tiyuri A; Baghermanesh SS; Davatgaran-Taghipour Y; Eslami SS; Shaygan N; Parsaie H; Barati M; Jafari D
Expert Rev Mol Diagn; 2023; 23(11):971-983. PubMed ID: 37715364
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model.
Fox R; Berhane S; Teng M; Cox T; Tada T; Toyoda H; Kumada T; Kagebayashi C; Satomura S; Johnson PJ
Br J Cancer; 2014 Apr; 110(8):2090-8. PubMed ID: 24691419
[TBL] [Abstract][Full Text] [Related]
13. Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?
Sha M; Cao J; Xia Q
J Hepatol; 2024 Apr; 80(4):e171-e172. PubMed ID: 37821020
[No Abstract] [Full Text] [Related]
14. Reply to: "Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?".
Norman JS; Mehta N
J Hepatol; 2024 Apr; 80(4):e172-e173. PubMed ID: 38154740
[No Abstract] [Full Text] [Related]
15. Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma.
Fares S; Wehrle CJ; Hong H; Sun K; Jiao C; Zhang M; Gross A; Allkushi E; Uysal M; Kamath S; Ma WW; Modaresi Esfeh J; Linganna MW; Khalil M; Pita A; Kim J; Walsh RM; Miller C; Hashimoto K; Schlegel A; Kwon DCH; Aucejo F
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672535
[TBL] [Abstract][Full Text] [Related]
16. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
17. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma.
Debes JD; Romagnoli PA; Prieto J; Arrese M; Mattos AZ; Boonstra A; On Behalf Of The Escalon Consortium
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918270
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma.
Pang BY; Leng Y; Wang X; Wang YQ; Jiang LH
Ann Med; 2023 Dec; 55(1):42-61. PubMed ID: 36476015
[TBL] [Abstract][Full Text] [Related]
19. Combination of serum alpha-fetoprotein, PIVKA-Ⅱ and glypican-3 in diagnosis of hepatocellular carcinoma: a meta-analysis.
Song H; Wang J; Zhang H; Wu Y; Wang K; Wang X; Xu X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 53(1):131-139. PubMed ID: 38310085
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and Prognostic Value of Protein Post-translational Modifications in Hepatocellular Carcinoma.
Wang J; Wang F; Wang N; Zhang MY; Wang HY; Huang GL
J Clin Transl Hepatol; 2023 Oct; 11(5):1192-1200. PubMed ID: 37577238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
